Your browser doesn't support javascript.
loading
Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases.
Xu, Jin-Gen; Jia, Huifeng; Chen, Shi; Xu, Jingyue; Zhan, Yifan; Yu, Haijia; Wang, Wei; Kang, Xi; Cui, Xiaopei; Feng, Yujie; Chen, Xiaofang; Xu, Wei; Pan, Xianfei; Wei, Xiaoyue; Li, Hui; Wang, Yanting; Xia, Simin; Liu, Xiaoyan; Yang, Lixiang; He, Yang; Zhu, Xiangyang.
Afiliação
  • Xu JG; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Jia H; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Chen S; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Xu J; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Zhan Y; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Yu H; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Wang W; BayRay Innovation Center, Shenzhen Bay Laboratory, Shenzhen 518055, China.
  • Kang X; Institute of Translational Research, Shenzhen Bay Laboratory, Shenzhen 518055, China.
  • Cui X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Feng Y; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Chen X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Xu W; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Pan X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Wei X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Li H; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Wang Y; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Xia S; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Liu X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China.
  • Yang L; BayRay Innovation Center, Shenzhen Bay Laboratory, Shenzhen 518055, China.
  • He Y; BayRay Innovation Center, Shenzhen Bay Laboratory, Shenzhen 518055, China. Electronic address: heyang@szbl.ac.cn.
  • Zhu X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai 201203, China. Electronic address: xiang.zhu@huaota.com.
Int J Biol Macromol ; 202: 529-538, 2022 Mar 31.
Article em En | MEDLINE | ID: mdl-35066019
ABSTRACT
The pro-inflammatory cytokine interleukin-17A (IL-17A) is a key driver of multiple inflammatory and immune disorders. Therapeutic antibodies targeting IL-17A have been proven effective in treating patients with these diseases; however, large variations in clinical outcomes have been observed with different antibodies. In this study, we developed HB0017, a novel monoclonal antibody that targets human IL-17A. HB0017 specifically and strongly bound to human, cynomolgus monkey, and mouse IL-17A at the physiological interface with the IL-17A receptor. In human and monkey cells, HB0017 potently antagonized the functions of IL-17A through competitive binding. HB0017 functioned equivalently to that of clinically approved antibodies in terms of therapeutic efficacy for inflammatory disorders and psoriasis in a mouse model. The results indicate that HB0017 may be an alternative biological therapy for treating patients with inflammation and autoimmune diseases.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Psoríase / Doenças Autoimunes Limite: Animals / Humans Idioma: En Revista: Int J Biol Macromol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Psoríase / Doenças Autoimunes Limite: Animals / Humans Idioma: En Revista: Int J Biol Macromol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China